Introduction
Systemic sclerosis (SSc) is a chronic connective tissue disease characterized by vascular damage, inflammation resulting in fibrosis in the skin and internal organs, and the presence of autoantibodies (1, 2) . SSc is mainly classified into diffuse and limited cutaneous forms (3) . The correlation between autoantibodies and clinical findings in SSc has been well established (4) . Antinuclear antibodies (ANAs) are present in 80%-95% of patients with SSc (2, 5) . Autoantibodies such as antitopoisomerase I antibody (ATA), anticentromere antibody (ACA), and anti-RNA polymerase III antibody (anti-RNAP III) are helpful for diagnosis and classification of SSc (5) (6) (7) (8) (9) . ATA is classically associated with the diffuse form (dcSSc) and ACA is typically associated with the limited form (lcSSc). ATA is also associated with pulmonary fibrosis and renal crisis. Anti-RNAP III is reported to be associated with dcSSc, renal crisis, and worse prognosis (10) .
In this study, we aimed to investigate the prevalence of anti-RNAP III and other autoantibodies in a group of patients with SSc and their relation with clinical features. This is also the first study investigating the prevalence of anti-RNAP III and its relation with clinical features in SSc patients in a Turkish population.
Materials and methods
SSc patients followed in the Department of Rheumatology of Ankara University Medical School referring between October 2014 and June 2015 were included in the study. Inclusion criteria for the patient group were diagnosis of SSc according to the classification criteria defined by the American College of Rheumatology (11) and being over 18 years of age. Patients were classified as having diffuse or limited cutaneous SSc according to LeRoy's classification (3) . Clinical data including sex, age, age at diagnosis, duration of disease, vascular symptoms, and visceral organ involvements were recorded. In patients with SSc, age at the first symptom except for Raynaud's phenomenon was accepted as the disease onset age. Presence of Raynaud's phenomenon, digital ulcers, arthritis, and extent of cutaneous sclerosis was based on history and physical examination. Pulmonary arterial pressure (PAP) was detected by echocardiography and elevated systolic PAP was defined as ≥40 mmHg. Lung involvement was defined as typical bilateral subpleural fine reticular to advanced fibrotic changes on high-resolution computed tomography with or without symptoms or functional test abnormality, gastrointestinal involvement as dysphagia and/or motility disorder without alternative etiology, and renal crisis as acute deterioration in kidney function with hypertension plus compatible renal biopsy findings. As controls, we studied the sera of 65 healthy blood donors and 86 patients with systemic lupus erythematosus (SLE). Written informed consent was obtained from each patient and control. The study was in compliance with the principles outlined in the declaration of Helsinki and was approved by the local ethics committee.
For analysis of autoantibodies, ANA was detected by indirect immunofluorescence with Hep-2 cells at a screening dilution of 1:100. Serum anti-RNAP III was measured using a commercial ELISA kit (Quanta Lite RNA Pol III, Inova Diagnostics, San Francisco, CA, USA). Presence of autoantibodies (ATA, anticentromere protein B [anti-CENP B], anti-PM/Scl, anti-Sm, anti-SS-A 52, anti-SS-A 60, and anti-SS-B) was assessed using a commercial test (IMTEC ANA Line Immune Assays Maxx, Human Diagnostics, Wiesbaden, Germany).
All calculations were performed with IBM SPSS for Windows version 21 software. The data were analyzed using the chi-square test for comparison between groups. Odds ratios (ORs) with 95% confidence intervals were calculated where appropriate. P < 0.05 was considered statistically significant.
Results
Clinical, laboratory, and demographic data are presented in Table 1 . Prevalences of anti-RNAP III positivity were 2/93 (2.2%) in SSc, 1/86 (1.2%) in SLE, and 1/65 (1.5%) in the healthy control group (P > 0.999).
Serum samples of 83 (89%) SSc patients and all SLE patients were available for analysis of presence of ANA.
The ANA staining pattern was studied for 80 (86%) SS patients and all SLE patients. Autoantibody specificities were studied for 82 (88%) SSc patients and all SLE patients. ANA was not evaluated in the healthy control group. SSc and SLE groups were compared in terms of ANA staining pattern and autoantibody specificities. The data are represented in Table 2 Table 3 .
dcSSc and lcSSc patients were compared in terms of ANA positivity, ANA staining patterns, and autoantibody specificities (Table 4) Anti-PM/SCL 1 (1.2) 0 N/A P = 0.304 ANA = Antinuclear antibody; SSc = systemic sclerosis; SLE = systemic lupus erythematosus; ATA = antitopoisomerase I antibody; OR = odds ratio; CI = confidence interval; N/A = not applicable. *Serum samples of 83 (89%) SSc patients and all SLE patients were available for analysis of ANA. The ANA staining pattern was studied in 80 (86%) SSc patients and in all SLE patients. Autoantibody specificities were studied in 82 (88%) SSc patients and in all SLE patients. All data are represented as number (percentages). SSc = Systemic sclerosis; dcSSc = diffuse cutaneous SSc; lcSSc = limited cutaneous SSc; n = number; PAP = pulmonary arterial pressure, years = years; SD = standard deviation; OR = odds ratio; CI = confidence interval. † Data are represented as numbers (percentages). ‡Four (29%) dcSSc patients and 22 (28%) lcSSc patients lacked echocardiographic PAP measurements.
Discussion
Prevalence of anti-RNAP III in SSc patients varies in previously published studies. In a cohort study from Pittsburgh, USA, prevalence was 25% (12) . In studies conducted in Europe it is found that prevalence decreases from north to south, being 22% in Sweden, 12% in England, 8% in Italy, and 5% in Poland. In a multicenter study performed in France, prevalence of anti-RNAP III was found to be 9.4%. Studies conducted in Asian countries observed a further decrease in the prevalence, at 6% in Japan and 3.4% in South Korea (6, (12) (13) (14) (15) (16) (17) . We found only two anti-RNAP III-positive cases among 93 SSc patients (2.2%). There are several reasons for the variation in prevalence. First, anti-RNAP III prevalence varies depending on the method used. In a study conducted in France, different results were obtained in evaluations made using two different ELISA kits (13, 18, 19) . Second, patient selection also affects the prevalence of anti-RNAP III. For example, in a study conducted by Parker et al., SSc patients were selected according to their ANA staining properties and a high prevalence (15.4%) was reported (20) . Another study was conducted among patients diagnosed with dcSSc and the prevalence was detected to be 67% (10) . Determination of different prevalences among the abovementioned studies, conducted in many different countries, raises concerns about race and ethnicity (19) . In our study, prevalence of anti-RNAP III was 2.2% in SSc cases, 1.2% in SLE cases, and 1.5% in healthy subjects and there was no significant difference between groups. The reason for this may be the relatively low number of patients, the cross-sectional manner of the study, and patient selection.
Prospective cohort studies will be more informative for true incidences and disease phenotype-autoantibody associations in patients with SSc. Previous studies have shown the associations of anti-RNAP III with higher modified Rodnan skin scores (mRSS), renal crisis, tendon friction rubs, and dcSSc (5,6-9). None of our SSc patients had a history of renal crisis and as a limitation we did not evaluate tendon friction rubs or mRSS. We had two anti-RNAP III-positive SSc patients, one with dcSSc and the other with lcSSc, and further statistical analysis was not possible.
Vascular phenomena (Raynaud's and digital ulcers) frequency and high pulmonary arterial pressure were found to be significantly less common in ANA-negative SSc patients than ANA-positive SSc patients (21) . In the same study, there was no significant relationship between ANA positivity and ILD and there was a significant relationship between negative ANA and gastrointestinal involvement. In our study, we detected no significant relationship between ANA positivity with abnormal capillaroscopy, Raynaud's phenomenon, digital ulcers, gastrointestinal involvement, and ILD. Despite the known association between high ACA titers and pulmonary hypertension (22) , we found no relationship between positive anti-CENP B and high systolic PAP.
Association between positive anti-SS-A 52 and the presence of digital ulcers was not reported before in patients with SSc, although anti-SS-A 52 was previously reported to be associated with pulmonary fibrosis in patients with mixed connective tissue disorder (23) . This issue requires a more detailed research.
Previous studies investigated the frequency of SScspecific autoantibodies in different ethnic groups (24) (25) (26) (27) . These studies have demonstrated that there are differences in the distribution of autoantibodies. We compared the results of these studies with our own data in Table 5 .
In conclusion, the prevalence of anti-RNAP III differs in different populations and is relatively low in Turkish patients with SSc.
